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Abstract
 
We have identified and characterized a novel src homology 2 (SH2) and pleckstrin homology
(PH) domain–containing adaptor protein, designated Bam32 (for B cell adaptor molecule of 32
kD). cDNAs encoding the human and mouse Bam32 coding sequences were isolated and the
 
human 
 
bam32
 
 gene was mapped to chromosome 4q25–q27. Bam32 is expressed by B lympho-
cytes, but not T lymphocytes or nonhematopoietic cells. Human germinal center B cells show
increased Bam32 expression, and resting B cells rapidly upregulate expression of Bam32 after li-
gation of CD40, but not immunoglobulin M. Bam32 is tyrosine-phosphorylated upon B cell
antigen receptor (BCR) ligation or pervanadate stimulation and associates with phospholipase
 
C
 
g
 
2. After BCR ligation, Bam32 is recruited to the plasma membrane through its PH domain.
Membrane recruitment requires phosphatidylinositol 3-kinase (PI3K) activity and an intact
 
PI(3,4,5)P
 
3
 
-binding motif, suggesting that membrane association occurs through binding to
3-phosphoinositides. Expression of Bam32 in B cells leads to a dose-dependent inhibition of
BCR-induced activation of nuclear factor of activated T cells (NF-AT), which is blocked by
deletion of the PH domain or mutation of the PI(3,4,5)P
 
3
 
-binding motif. Thus, Bam32 repre-
sents a novel B cell–associated adaptor that regulates BCR signaling downstream of PI3K.
Key words: immunoglobulin • germinal center • signal transduction • SH2 domain • 
pleckstrin homology domain
 
Introduction
 
The population of B lymphocytes present in peripheral
lymphoid tissues is dynamically maintained by processes
that balance the continuous output from the bone marrow
and proliferation in response to antigens with B cell termi-
nal differentiation and death. The choices between the al-
ternative fates of proliferation, differentiation, and death,
are largely determined by intracellular signaling cascades
triggered by receptor–ligand interactions. The B cell anti-
gen receptor (BCR)
 
1
 
 is a central regulator of B cell fate (1,
2). BCR signaling is required for survival and recirculation
of naive B cells (3) as well as for antigen-specific immune
responses. Ligation of the BCR by antigen can have differ-
ent outcomes depending on the differentiation stage of the
B cell, the molecular form of antigen, and the immunolog-
ical context of the antigen encounter (4, 5). These different
outcomes can be due to differences in quality or quantity of
signals emanating from the BCR itself (4, 6) and/or differ-
ential signaling through other key receptors such as CD19,
CD22, CD40, CD72, CD95, CDw150, and Fc
 
g
 
RII (1, 7,
8). These coreceptors can act by directly modifying recep-
tor-proximal events in BCR signaling or by activating ad-
ditional signaling pathways which influence the outcome
of BCR signaling.
 
Address correspondence to Aaron J. Marshall, Department of Microbiol-
ogy, University of Washington, Seattle, WA 98195. Phone: 206-543-
7414; Fax: 206-543-8297; E-mail: aaronn@u.washington.edu
 
1
 
Abbreviations used in this paper:
 
 Bam32, B cell adaptor molecule of 32 kD;
BCR, B cell antigen receptor; BLNK, B cell linker; Btk, Bruton’s ty-
rosine kinase; EGFP, enhanced green fluorescent protein; FDC, follicular
dendritic cell; FISH, fluorescence in situ hybridization; G3PDH, glyceral-
dehyde 3-phosphate dehydrogenase; GC, germinal center; GST, glu-
tathione 
 
S
 
-transferase; NF-AT, nuclear factor of activated T cells; NF-
 
k
 
B, nuclear factor of 
 
k
 
 binding; PdBu, phorbol-12,13-dibutyrate; PH,
pleckstrin homology; PI, phosphatidylinositol; PI3K, phosphatidylinositol
3-kinase; PLC, phospholipase C; PTK, protein tyrosine kinase; RACE,
rapid amplification of cDNA ends; RT, reverse transcription; SH2, src
homology 2; SSH, suppression subtractive hybridization. 
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Ligation of the BCR leads to activation of nonreceptor
protein tyrosine kinases (PTKs), which regulate several
downstream signaling pathways (1, 2). These include phos-
pholipase C (PLC)
 
g
 
, which, upon activation, hydrolyzes
phosphatidylinositol (4,5) bisphosphate (PI(4,5)P
 
2
 
) to pro-
duce inositol 1,4,5 trisphosphate (IP
 
3
 
), which triggers the
release of calcium from intracellular stores, and diacylglyc-
erol (DAG), which can activate protein kinase C isoforms.
Other pathways that are activated downstream of PTKs in-
clude the Ras pathway (9) and the phosphatidylinositol
3-kinase (PI3K) pathway (10). Activation of PI3K leads to
activation of the serine/threonine kinase Akt (11, 12) and
regulates the membrane association and function of the Tec
family PTK, Bruton’s tyrosine kinase (Btk) (13, 14). Adap-
tor proteins such as B cell linker (BLNK), which contain
protein–protein interaction domains but no catalytic activ-
ity, play critical roles in linking BCR-induced PTK activa-
tion to downstream effectors (15, 16). The BCR signaling
cascade ultimately leads to activation of transcription factors
such as nuclear factor of activated T cells (NF-AT) and nu-
clear factor of 
 
k
 
 binding (NF-
 
k
 
B) (17–20). In at least one
case, alternative outcomes of BCR signaling correlate with
differential activation of these transcription factors (6).
During B cell responses to thymus-dependent antigens,
key B cell activation and differentiation events occur
within germinal centers (GCs) (21, 22). The GC response
is initiated when B cells activated by encounter with anti-
gen and cognate T cell help migrate to the B cell follicles
and begin proliferating rapidly in association with the follic-
ular dendritic cell (FDC) network to give rise to a GC.
GC B cells begin a complex differentiation program that
incorporates somatic hypermutation coupled with selection
for high-affinity antigen-specific Ig, Ig class switching, and
differentiation into memory B cells or plasma cells. GC B
cells represent a distinct differentiation state and display sev-
eral unique properties such as a predisposition to apoptosis
and reexpression of genes expressed during early B cell de-
velopment (21–23). The molecular basis for B cell activa-
tion and differentiation processes occurring within GCs is
poorly understood. In this study, we have undertaken a
screen for GC-associated genes and report the identification
and characterization of a novel B cell–restricted signaling
molecule that is highly expressed in GC B cells and appears
to regulate B cell activation pathways downstream of PI3K.
 
Materials and Methods
 
Isolation of the Bam32 cDNA.
 
Enriched FDC populations
were obtained from human tonsils according to the method of
Liu et al. (24). Cells (10
 
6
 
) were pooled from three prepara-
tions, total RNA was isolated, and double-stranded cDNA
was produced using the switching mechanism at RNA termini
(SMART) PCR cDNA synthesis method (Clontech). PCR anal-
ysis of the resulting cDNA using primers that can distinguish
FDC and B cell isoforms of CD21 (24) indicated that both iso-
forms were present in approximately equal proportions (data not
shown). A double-stranded driver cDNA was concomitantly pro-
duced by the same method using an equal mixture of RNA from
 
the fibroblast cell lines HFF and 122 and the epithelial line HeLa.
A suppression subtractive hybridization (SSH) PCR subtraction
procedure was carried out according to the manufacturer’s proto-
col (PCR Select; Clontech), using the FDC cDNA as tester and
the fibroblast/epithelial cell cDNA as driver. The pool of differ-
entially expressed gene fragments generated was then cloned into
the pCRII vector (Invitrogen), and 60 clones were randomly
picked and screened for differential expression using tester and
driver cDNA probes. Differentially expressed clones were se-
quenced by dye-terminator sequencing (PE Biosystems). The
Bam32 SSH fragment was used as a probe to screen a human
lymph node cDNA library, and several positive clones were ob-
tained and sequenced. A fragment of the murine Bam32 cDNA
was obtained by low stringency reverse transcription (RT)-PCR,
and then the entire cDNA was obtained using rapid amplification
of cDNA ends (RACE) with an adaptor-ligated cDNA template
derived from Balb/c spleen (Clontech).
 
Fluorescence In Situ Hybridization.
 
Plasmids containing 5
 
9
 
 and
3
 
9
 
 fragments of the Bam32 cDNA were labeled with biotin-11-
dATP by nick translation (GIBCO BRL). Metaphase chromo-
some preparations from lymphocytes of a human male were ob-
tained using 0.075 M KCl as a hypotonic buffer and methanol/
acetic acid (3:1 vol/vol) as a fixative. Hybridization was carried
out as described previously (25). The chromosomes were banded
using Hoechst 33258–actinomycin D staining and counterstained
with propidium iodide. The chromosomes and hybridization sig-
nals were visualized by fluorescence microscopy using a dual
bandpass filter (Omega).
 
Northern Blot and RT-PCR Expression Analysis.
 
A 
 
32
 
P-labeled
Bam32 cDNA probe was hybridized to human multiple tissue
Northern blots (Clontech) and to a Northern blot containing
2 
 
m
 
g of poly A
 
1
 
 RNA from human tonsils, according to the
manufacturer’s protocol. For RT-PCR analysis, 2 
 
m
 
g of total
RNA from the indicated cell lines was reverse transcribed using
Superscript II reverse transcriptase (GIBCO BRL). 1/10 of the
resulting cDNA was subjected to PCR amplification for 30 cycles
using Bam32-specific primers TGTCTCACAGAGCGAGAAG-
GTGTCAGG and GAACCATCAGAGTGCCTGTCTCGCT-
TCC or glyceraldehyde-3-phosphate dehydrogenase (G3PDH)
control primers TGAAGGTCGGAGTCAACGGATTTGGT
and CATGTGGGCCATGAGGTCCACCAC. The resulting
PCR products were run on agarose gels, Southern blotted, and
hybridized with oligonucleotide probes: CTCTACCTCTGT-
GAAGGGCGCGAATG (Bam32) and TGGGCGCCTGGT-
CACCAGGGCTGCTT (G3PDH).
For analysis of Bam32 expression in primary B cell subsets,
tonsillar B cells were prepared as described (26), stained with
FITC-labeled anti-IgD (mAb 
 
d
 
STA4-1) and PE-labeled anti-
CD38 (Immunotech), and sorted into IgD
 
1
 
CD38
 
2
 
 (naive),
IgD
 
2
 
CD38
 
1
 
 (GC), and IgD
 
2
 
CD38
 
1
 
 (memory) fractions (27) us-
ing a FACStar
 
PLUS™
 
 instrument (Becton Dickinson). For in vitro
stimulation experiments, naive (high density) B cells were pre-
pared by Percoll fractionation of tonsillar B cells, as described
(26). Cells were stimulated with 2 
 
m
 
g/ml anti-CD40 (mAb G28-5)
and harvested at the indicated time. The indicated dilution of
first-strand cDNA was used for PCR amplification as above.
 
Expression Constructs and Antibodies.
 
Eukaryotic expression
vectors were generated by inserting the full-length coding se-
quence or sequence encoding amino acids 1–142 (
 
D
 
PH COOH-
terminal truncation mutant) into pcDNA3 (Invitrogen). Myc-
tagged Bam32 expression vector was generated by inserting
the Bam32 coding sequence into pcDNA3.1 myc/hisA (Invitro-
gen) in frame with the myc tag. Constructs encoding Bam32– 
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enhanced green fluorescent protein (EGFP) fusion proteins were
generated by inserting either sequence encoding the full-length
protein (EGFP-Bam32), amino acids 1–142 (EGFP-SH2), or
amino acids 133–280 (EGFP-PH) into the pEGFP-C1 vector
(Clontech). R61K, R184C, and K197E point mutants were gen-
erated with mutant PCR primers using the splicing by overlap
extension (SOE) method (28) and inserted into pEGFP-C1 (PH
domain only) or pcDNA3 (full-length). The Btk PH domain
construct contains amino acids 1–195 inserted into pEGFP-C1.
Prokaryotic expression vectors encoding a Bam32 SH2 domain
(amino acids 1–142)–glutathione 
 
S
 
-transferase (GST) fusion pro-
tein or a full-length Bam32-GST fusion protein were generated
by inserting the appropriate Bam32 coding sequence into the
pGEX 5-x-2 vector (Amersham Pharmacia Biotech). Fusion pro-
teins were purified with glutathione-sepharose beads (Amersham
Pharmacia Biotech), according to the manufacturer’s protocol.
An anti-Bam32 serum (4210K) was generated by immunizing
rabbits with a Bam32-GST fusion protein. A Bam32-specific
mAb (UW32; IgG1 isotype) was generated by immunizing mice
with Bam32-GST fusion protein, followed by fusion with NS-1
cells and ELISA screening of clones for reactivity against Bam32-
GST but not GST alone. Other antibodies used were biotiny-
lated phosphotyrosine-specific mAb 4G10 (Upstate Biotechnol-
ogy), anti-myc mAb 9E10, anti-BLNK mAb 2C9 (Santa Cruz
Biotechnology), and affinity-purified rabbit anti-PLC
 
g
 
1 and anti-
PLC
 
g
 
2 sera (Santa Cruz Biotechnology).
 
Transient Transfection of BJAB Cells.
 
For transient transfec-
tion experiments, BJAB cells were resuspended in tissue culture
medium at 3 
 
3 
 
10
 
7
 
/ml and 400 
 
m
 
l of cells was mixed with the
indicated amount of plasmid constructs in a 0.4-cm-gap elec-
troporation cuvette (Bio-Rad) and incubated on ice for 10 min.
Cells were then electroporated using a Gene Pulser apparatus
(Bio-Rad) set at 240 V, 960 
 
m
 
F, incubated on ice for a further 10
min, and then transferred to a tissue culture dish containing 20 ml
of complete RPMI medium containing 15% FCS and no antibi-
otics and incubated overnight in a 37
 
8
 
C, 5% CO
 
2
 
 incubator.
Cells were then harvested, counted, and used in the indicated as-
says.
 
Immunoprecipitation and Blotting.
 
For stimulation experi-
ments, Ramos cells were resuspended at 2 
 
3 
 
10
 
7
 
/ml and stimu-
lated for the indicated periods of time with 10 
 
m
 
g/ml of goat
anti–human IgM F(ab
 
9
 
)
 
2
 
 fragments (Jackson ImmunoResearch
Laboratories) or 2.5 mM of H
 
2
 
O
 
2
 
 plus 250 
 
m
 
M of sodium ortho-
vanadate (referred to as pervanadate), washed with 10 vol of ice-
cold PBS containing 0.1% sodium azide, and lysed at 4 
 
3 
 
10
 
7
 
cells/ml in NP-40 lysis buffer (150 mM NaCl, 50 mM Tris, pH
8.0, 5 mM EDTA, 0.5% NP-40, protease inhibitors [2 mM
PMSF, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, and 1 
 
m
 
g/ml
pepstatin], and phosphatase inhibitors [10 mM NaF, 1 mM
Na
 
3
 
VO
 
4
 
, and 5 mM Na
 
4
 
P
 
2
 
O
 
7
 
]). Immunoprecipitation, SDS-
PAGE, and Western blot analysis were conducted as described
(29). Far-Western blotting with the Bam32 SH2 domain–GST
fusion protein were performed as described (30).
 
Confocal Microscopy Analysis of GFP Fusions.
 
10 
 
m
 
g of the in-
dicated pEGFP vectors was transfected into BJAB cells by elec-
troporation. After 18–20 h, cells were harvested, washed, and
rested overnight in low-serum medium (1.25% FCS). This ma-
nipulation reduced the basal membrane association of the PH do-
main–containing fusion proteins. Cells were then harvested and
resuspended at 4–6 
 
3 
 
10
 
6
 
/ml in low-serum medium. Cells were
incubated for 30 min at 37
 
8
 
C with or without PI3K inhibitors
wortmannin (20 ng/ml; Calbiochem) or LY294002 (25 
 
m
 
M;
Calbiochem), and then stimulated with 10 
 
m
 
g/ml goat anti–
 
human IgM F(ab
 
9
 
)
 
2
 
 fragments for the indicated time. Cells were
then washed in 10 vol of ice-cold PBS, fixed in 2% paraformalde-
hyde/PBS for 30 min at room temperature, washed twice in
PBS, and then mounted on slides using an aqueous mounting so-
lution (Aqua Polymount; Polysciences, Inc.). EGFP fluorescence
was examined using a scanning laser confocal microscope
equipped with LaserSharp software (MRC-1024 system; Bio-
Rad). The ratio of membrane to cytoplasmic EGFP fluorescence
intensity was determined from digital images using ImageQuant
 
®
 
software (Molecular Dynamics). For each cell, the peak pixel in-
tensity at 4 points on the plasma membrane was averaged and di-
vided by the average pixel intensity within a defined area of cyto-
plasm (avoiding the nucleus).
 
Luciferase Assays.
 
BJAB B cells were transfected by electropo-
ration with pcDNA3 expression vectors containing wild-type or
mutant Bam32 and an NF-AT-luciferase reporter construct (gift
from Dr. Gary Koretzky, University of Iowa, Iowa City, IA). Af-
ter 18–20 h, cells were harvested and plated in 96-well plates at
2 
 
3 
 
10
 
5
 
/well. Triplicate cultures were incubated in media alone,
with 5 
 
m
 
g/ml anti-IgM F(ab
 
9
 
)
 
2
 
 fragments or 50 nM phorbol-
12,13-dibutyrate (PdBu; Calbiochem) and 2.5 
 
m
 
M ionomycin
(Calbiochem). After 6 h, the cells were lysed and luciferase activ-
ity was measured as described (31).
 
Results
 
Cloning of Bam32, A Novel GC-associated Signaling Adaptor.
 
To identify genes expressed in GCs, we carried out an
SSH experiment using an enriched preparation of hu-
man FDCs as a source of tester cDNA (see Materials and
Methods). PCR analysis indicated that our tester cDNA in-
cluded both transcripts derived from FDCs and transcripts
derived from adhering B cells (data not shown). One of the
differentially expressed clones isolated from this subtraction
experiment contained a partial coding sequence for a novel
SH2 domain–containing protein. Several cDNA clones
containing the entire protein coding sequence for this gene
were obtained by screening a human lymph node cDNA
library. The cDNA sequence predicts a 32-kD protein
containing an NH
 
2
 
-terminal SH2 domain and a COOH-
terminal PH domain, but lacking any known catalytic do-
mains (Fig. 1 A). The sequence contains 10 tyrosines, 1 of
which matches the consensus motif for a tyrosine-phos-
phorylation site. Thus, this molecule represents a new
member of the adaptor class of signaling molecules. Based
on this structure and the restricted expression pattern of this
gene (see below), we have designated this molecule Bam32
for B lymphocyte adaptor molecule of 32 kD.
The murine Bam32 homologue was isolated by low
stringency PCR, followed by RACE (Fig. 1 A). Murine
Bam32 shares 96.7% sequence identity with the human
protein within the central portion containing the SH2 and
PH domains. In contrast, the NH
 
2
 
-terminal region is less
well conserved (76.5% identity), while the COOH-termi-
nal 20 amino acids are completely different than our hu-
man clones. However, the expressed sequence tag (EST)
database contains an alternatively spliced human Bam32
cDNA sequence that encodes a COOH-terminal sequence
corresponding to our mouse Bam32 clone (82.6% iden- 
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tity). We designate the two human splice forms hbam1 and
hbam2 and the corresponding murine sequence mbam1
(Fig. 1 A). The chromosomal location of the human
Bam32 gene was determined by fluorescent in situ hybrid-
ization (FISH) on banded human metaphase chromosomes.
In the majority of cells examined (44/67), clear signals
were observed on both chromatids of chromosome 4 at
band q25–q27 (Fig. 1 B).
 
Bam32 Is Expressed by B Lymphocytes, but Not T Cells or
Nonhematopoietic Cells.
 
Expression of Bam32 in human
tissues was determined by Northern blot analysis (Fig. 2
A). Our Bam32 cDNA probe detects both a predominant
2.9-kb transcript, corresponding in size to our largest
cDNA clones, and a much less abundant 4.4-kb transcript.
Bam32 transcripts are detected in all hematopoietic tissues
tested (bone marrow, spleen, lymph node, and peripheral
blood leukocytes) with the exception of the thymus,
which shows little or no expression. Bam32 expression was
also observed in trachea and placenta, but not in 14 other
nonlymphoid tissues including brain, heart, kidney, liver
and skeletal muscle, indicating that expression is largely
confined to cells of the immune system. Consistent with
the restricted tissue distribution pattern, RT-PCR analyses
Figure 1. Amino acid sequence of
Bam32 and localization of the Bam32 gene
to human chromosome 4q25–q27. In a
screen for genes selectively expressed in hu-
man GC cells, we identified Bam32, a novel
signaling adaptor protein containing an SH2
and a PH domain (see Materials and Meth-
ods). (A) Amino acid sequence of human
and mouse Bam32, with the SH2 domain
indicated by black underline and the PH
domain indicated by gray underline. The
putative tyrosine-phosphorylation site is
boxed. We have sequenced three cDNA
clones and a RACE product corresponding
to the hbam1 splice form. The COOH-ter-
minal sequence of the hbam2 splice form,
which corresponds to our mouse Bam32
clone, is derived from expressed sequence
tag sequences (accession nos. AA459342
and AF150266). The Bam32 cDNA se-
quence is available from EMBL/GenBank/
DDBJ under accession nos. AF186022 (hu-
man) and AF186023 (mouse). (B) FISH
analysis showing the chromosomal location
of the human Bam32 gene.
Figure 2. Cell type–specific expression of Bam32 mRNA. (A) North-
ern blot analysis of Bam32 expression in human tissues, showing highest
levels of expression in lymphoid tissues and trachea. (B) RT-PCR analysis
of Bam32 expression in a panel of cell lines, showing B lymphocyte–
restricted expression. 
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indicated that Bam32 is expressed in all B cell lines exam-
ined, but not in T cell, epithelial cell, fibroblast, or myelo-
cytic leukemia lines (Fig. 2 B). As expected, Bam32 tran-
scripts were detected in the sort-enriched tonsillar FDC
tester RNA, but not in the fibroblast pool driver RNA.
 
Bam32 Expression Is Increased upon B Cell Activation.
 
Since Bam32 was isolated as a GC-associated gene, it was
of interest to compare the expression of Bam32 at different
stages of B cell differentiation. Therefore, we fractionated
human tonsillar B cells into naive, GC, and memory sub-
sets on the basis of CD38 and IgD expression (27). While
Bam32 transcripts were detected in all fractions, GC B cells
expressed fourfold higher levels than naive B cells (Fig. 3
A). Furthermore, the memory B cell fraction expressed 15-
fold lower levels of Bam32 transcripts than GC B cells.
These results suggest that Bam32 expression levels are
modulated during B cell activation and differentiation. To
further investigate the activation signals that might regulate
Bam32 expression, resting B cells were stimulated in vitro
with CD40 antibodies and Bam32 expression was deter-
mined. CD40 ligation led to a 5–10-fold increase in
Bam32 expression, whereas BCR ligation had no signifi-
cant effect (Fig. 3 B). Together, these results suggest that
Bam32 expression is specifically increased during T cell–
dependent activation, is maintained at high levels during
the subsequent GC response, and then decreases upon dif-
ferentiation to memory B cells.
 
Bam32 Is Phosphorylated on Tyrosine and Associates with
PLC
 
g
 
2 after BCR Ligation or Pervanadate Stimulation.
 
To
determine whether Bam32 associates with tyrosine-phos-
phorylated proteins after B cell activation, Bam32 was im-
munoprecipitated from lysates of resting or activated B
cells and the precipitates were run on SDS-PAGE and
blotted with biotinylated phosphotyrosine-specific mAb
followed by streptavidin-peroxidase (Fig. 4 A). Two pre-
dominant tyrosine-phosphorylated proteins running at
 
z
 
140 and 35/36 kD were detected in Bam32 immuno-
precipitates from BCR- or pervanadate-stimulated Ramos
cells. As expected, neither of these bands was observed in
immunoprecipitates from pervanadate-stimulated Jurkat
cells, which do not express Bam32. We found no evidence
for a phosphoprotein running at 32 kD; however, when
Bam32 immunoprecipitates were blotted with polyclonal
Figure 3. Bam32 expression is increased after B cell activation. (A) Ex-
pression of Bam32 in primary B cell subsets. Tonsil B cells were fraction-
ated into naive, GC, and memory cell subsets by CD38 and IgD expres-
sion (reference 27), and Bam32 expression was determined by RT-PCR,
using cDNA dilutions falling within the linear amplification range. Rela-
tive Bam32 expression was determined by normalizing the Bam32 signal
to the G3PDH signal for each sample and are expressed as values relative
to total B cells. Similar results were observed in two independent cell pu-
rifications. (B) Bam32 expression is increased after CD40, but not IgM li-
gation. Resting tonsillar B cells were prepared by Percoll fractionation
and then stimulated in vitro with anti-CD40 mAb, goat anti–human IgM
F(ab9)2 antibodies, or both. Cells were harvested after 14 h of culture, and
Bam32 expression was determined by RT-PCR using a series of 10-fold
dilutions of the cDNAs. Relative Bam32 expression was determined as in
A, using cDNA dilutions falling within the linear amplification range.
Bam32 upregulation could be observed as early as 6 h after CD40 ligation
(data not shown). Results are representative of three experiments.
Figure 4. Bam32 is phosphorylated on ty-
rosine and associates with a phosphoprotein
140 after B cell activation. (A) Coimmunopre-
cipitation of Bam32 with tyrosine-phosphory-
lated proteins. Ramos or Jurkat cells were stim-
ulated as indicated (IgM, goat anti–human IgM F(ab9)2; PV, pervanadate), lysed in NP-40 lysis
buffer, and immunoprecipitated with Bam32 mAb UW32 or control IgG1 mAb. Proteins present
in the immunoprecipitates were separated on a 12.5% SDS-PAGE gel, and blotted with biotiny-
lated antiphosphotyrosine (top) or rabbit anti-Bam32 serum (bottom). The positions of the molecu-
lar weight markers (in kD) are indicated. The upper arrow indicates the coprecipitating 140-kD
band, and the lower arrows indicated the position of Bam32 (black arrow) or tyrosine-phosphory-
lated Bam32 (grey arrow). (B) BJAB cells were transiently transfected with either empty pcDNA3
vector or pcDNA3 encoding myc epitope–tagged Bam32. Before and after stimulation with per-
vanadate, cells were lysed and a portion of the lysate was used for anti-myc Western blot to detect
the bandshift of myc-tagged Bam32 (left). The remainder of the lysates were immunoprecipitated
with anti-myc and blotted with antiphosphotyrosine to detect phosphorylation of Bam32 (right).1324 Bam32: A Novel Adaptor Protein Regulating B Cell Activation
Bam32 antibodies, an additional band of z35/36 kD was
detectable after BCR or pervanadate activation (Fig. 4 A,
bottom). This band was not present in unstimulated cells
and comigrated with the 35/36 kD band detected by an-
tiphosphotyrosine blotting, indicating that it represents ty-
rosine-phosphorylated Bam32. Consistent with this con-
clusion, myc epitope–tagged Bam32 also underwent a
bandshift and was tyrosine-phosphorylated after pervana-
date stimulation (Fig. 4 B).
Western blot analyses identified the 140-kD associated
protein as PLCg2, whereas neither PLCg1 nor BLNK
could be detected in Bam32 immunoprecipitates (Fig. 5
A). Although we can detect some constitutive association
of Bam32 with PLCg2, association is substantially in-
creased after activation (Fig. 5 B). A Bam32 SH2 domain
fusion protein bound in vitro to tyrosine-phosphorylated
PLCg2 immobilized on a nitrocellulose membrane, but
not to CD22 (Fig. 5 C), syk, or SH2 domain–containing
inositol 5-phosphatase (SHIP) (data not shown), suggesting
that the Bam32–PLCg2 interaction is direct and mediated
by the SH2 domain. Weak binding of the Bam32 SH2 fu-
sion protein to PLCg1 was also detected under these con-
ditions (Fig. 5 C, and data not shown). These results indi-
cate that Bam32 can interact with tyrosine-phosphorylated
signaling molecules after B cell activation through its SH2
domain and may function in part by regulating the activity
and/or location of PLCg2.
Bam32 Is Recruited to the Plasma Membrane after BCR
Cross-Linking Via Its PH Domain. We hypothesized that
Bam32 may associate with the plasma membrane through
binding of its PH domain to phosphoinositides generated
by PI3K, as observed with a subset of PH domain–con-
taining proteins, including Btk in B cells (14, 32, 33). To
determine the subcellular localization of Bam32 before and
after BCR cross-linking, we transfected BJAB B cells with
constructs encoding EGFP or EGFP fused to Bam32 and
examined the subcellular localization of the fusion proteins
by confocal fluorescence microscopy. While the native
EGFP showed only diffuse cytoplasmic and nuclear signal,
a proportion of the EGFP-Bam32 fusion protein was asso-
ciated with the plasma membrane (Fig. 6 A). Membrane
localization of Bam32-EGFP was increased by approxi-
mately threefold after BCR cross-linking (Fig. 6 A, and
data not shown). To determine which domains of Bam32
are required for membrane association, the NH2-terminal
half of Bam32 containing the SH2 domain or the COOH-
terminal half containing the PH domain was indepen-
dently expressed as a fusion with EGFP. We found that
the SH2 domain fusion localized to the cytoplasm, whereas
Figure 5. Bam32 associates with
PLCg2 through its SH2 domain. (A)
Bam32 coimmunoprecipitates with
PLCg2, but not PLCg or BLNK. Ra-
mos cells were stimulated with pervana-
date for 2 min, lysed, immunoprecipi-
tated with UW32, and blotted with
either anti-PLCg1 or anti-PLCg2 sera.
Ramos whole cell lysate was included as
a positive control. (B) Inducible associa-
tion of Bam32 with PLCg2. BJAB cells
were stimulated for 5 min with pervana-
date (PV) or left unstimulated, then im-
munoprecipitated with UW32, and
blotted with anti-PLCg2 antibodies. (C)
The Bam32 SH2 domain can directly
bind tyrosine-phosphorylated PLCg.
Lysates from pervanadate-stimulated
Ramos cells were immunoprecipitated
with the indicated antibodies and blot-
ted with a Bam32 SH2 domain–GST
fusion protein, followed by anti-GST
mAb (far-Western blot). A duplicate
membrane was blotted with antiphos-
photyrosine to confirm the presence of
the immunoprecipitated proteins.
Figure 6. Bam32 is recruited to the plasma membrane after BCR liga-
tion through its PH domain. BJAB B cells were electroporated with con-
structs encoding EGFP fused to Bam32 or individual domains of Bam32.
18–20 h after transfection, cells were harvested and replated in medium
containing 1.25% FCS. The next day, cells were harvested, stimulated
with anti-IgM F(ab9)2 fragments for 5 min, fixed, and mounted on slides.
EGFP fluorescence was visualized using a scanning laser confocal micro-
scope. (A) Bam32 associates with the plasma membrane through its PH
domain. (B) Membrane recruitment kinetics of the Bam32 PH domain
versus the BTK PH domain. Digital images of EGFP fluorescence were
used to determine the ratio of membrane to cytoplasmic fluorescence in-
tensity, as described in Materials and Methods. The graph indicates the
average and standard error for six to nine cells per point, pooled from two
anti-IgM stimulation experiments. Images representative of those used to
generate the quantitative data are shown.1325 Marshall et al.
the PH domain fusion showed a clear association with the
plasma membrane that increased after BCR ligation (Fig. 6
A). The full-length Bam32 fusion and the PH domain fu-
sion show similar levels of basal and induced membrane as-
sociation, indicating that the PH domain is both necessary
and sufficient for membrane recruitment.
The surprisingly high basal level of Bam32 membrane
association in BJAB B cells, which was not observed with
the Btk PH domain in NIH 3T3 cells (14), prompted us to
compare the relative levels and kinetics of membrane asso-
ciation of the Bam32 and Btk PH domains after BCR liga-
tion (Fig. 6 B). By quantifying relative fluorescence levels
in the plasma membrane versus the cytoplasm at various
time points after stimulation, we found that membrane re-
cruitment of the Bam32 PH domain was evident within 1
min of BCR stimulation, peaks at z5 min, and then
slowly declines back to basal levels. The Btk PH domain
was recruited with similar kinetics; however, a significantly
lower proportion of the fusion protein is present at the
plasma membrane (relative to the cytoplasm) at each time
point, and membrane association was not observed in un-
stimulated cells (Fig. 6 B). Unlike Bam32, a significant
proportion of the Btk PH domain fusion protein localized
to the nucleus as observed previously (14). These results
suggest that the Bam32 PH domain is rapidly and quantita-
tively recruited to the plasma membrane after BCR liga-
tion, and may have a higher selectively for binding to the
activated plasma membrane than the Btk PH domain.
Recruitment of the Bam32 PH Domain to the Plasma
Membrane Is Dependent on PI3K Activity and an Intact
PI(3,4,5)P3-binding Motif. We examined whether mem-
brane association of the Bam32 PH domain was dependent
on PI3K activity by preincubating cells expressing EGFP-
Bam32 or EGFP-Bam32 PH domain fusion proteins with
two structurally unrelated PI3K inhibitors, wortmannin or
LY294002, before BCR ligation (Fig. 7 A). These inhibi-
tors blocked membrane association of both fusion proteins,
demonstrating that membrane association of both the PH
domain and Bam32 as a whole is dependent on PI3K ac-
tivity. Alignment of the Bam32 PH domain with other PH
domains reveals that Bam32 contains a series of amino ac-
ids in the b2 and b3 strands that are conserved among
PI(3,4,5)P3-binding PH domains (32), including the argi-
nine corresponding to R28 in Btk, which is mutated in hu-
man X-linked agammaglobulinemia patients (34) and Xid
mice (35), and which forms part of the PI(3,4,5)P3-binding
pocket (36, 37). To test whether membrane association of
the Bam32 PH domain requires the conserved arginine in
this putative PI(3,4,5)3-binding pocket, we generated a
construct encoding EGFP fused to the Bam32 PH domain
bearing an R184C mutation. The R184C mutation com-
pletely abrogated membrane association (Fig. 7 B), provid-
ing support for the hypothesis that the PI3K-dependent as-
sociation of the Bam32 PH domain occurs through direct
binding to PI(3,4,5)3. Interestingly, when aligned with the
Btk PH domain, the Bam32 PH domain also contains an
amino acid substitution in the b3 strand found in a gain-
of-function Btk mutant that shows constitutive membrane
association (E41K; references 14, 38). To examine the role
of this residue in Bam32 membrane association, we gener-
ated a K197E mutant PH domain and examined mem-
brane association (Fig. 7 B). Surprisingly, the K197E mu-
tation also completely disrupted membrane association,
suggesting that this residue, which is not conserved among
phosphoinositide-binding PH domains, has a critical role
in phosphoinositide binding of the Bam32 PH domain.
We have confirmed the effect of the R28C and K41E mu-
tations on membrane association by immunofluorescence
staining of full-length Bam32 proteins expressed in BJAB
cells (data not shown). Together, the results in Figs. 6 and
7 suggest that, after BCR ligation, Bam32 is recruited to
the plasma membrane at sites of PI3K activation through
binding to PI(3,4,5)P3 in a manner analogous to Btk.
Bam32 Can Modulate BCR-induced Transcriptional Activa-
tion. To determine whether the presence of Bam32 in
membrane-associated signaling complexes can regulate sig-
naling through the BCR, we assessed the effect of overex-
pressing wild-type or mutant Bam32 proteins, using
downstream transcriptional activation as a readout for
BCR signaling. Bam32 expression constructs were
cotransfected into BJAB cells with a luciferase reporter
construct that allows measurement of transcription medi-
ated by NF-AT, a family of transcription factors that are
important regulators of both B and T cell activation re-
sponses (17, 18, 39–42). Strikingly, expression of wild-type
Bam32 inhibited BCR-induced activation of NF-AT in a
dose-dependent manner (Fig. 8 A), suggesting that modu-
Figure 7. Membrane recruitment of Bam32 requires PI3K activity and
a functional PI(3,4,5)P3-binding motif. BJAB B cells were electroporated
with constructs encoding EGFP fusion constructs and analyzed as in the
legend to Fig. 5. (A) Preincubation with PI3K inhibitors blocks membrane
recruitment of Bam32. Cells were pretreated for 30 min with 20 nM
wortmannin or 25 mM LY294002 at 378C before anti-IgM stimulation (5
min). Results are representative of five experiments. (B) Mutations in the
putative PI(3,4,5)P3-binding pocket of the Bam32 PH domain abrogate
membrane recruitment. Data are representative of two experiments.1326 Bam32: A Novel Adaptor Protein Regulating B Cell Activation
lation of Bam32 dose during B cell differentiation (Fig. 3)
could affect the outcome of BCR ligation. The observed
decrease in NF-AT activation is due to modulation of
BCR signaling pathways, since Bam32 expression level
had no significant affect on cell viabilities or levels of NF-
AT activation induced by phorbol ester and ionomycin
(data not shown). Deletion of the PH domain abrogated
the ability of Bam32 to inhibit BCR-induced NF-AT acti-
vation, whereas mutation of the invariant arginine of the
SH2 domain to lysine (R61K) had no significant effect
(Fig. 8 B). Cells expressing full-length Bam32 containing
the R184C or K197E mutations showed similar or slightly
increased BCR-induced NF-AT activation compared with
controls (Fig. 8 C), indicating that PI(3,4,5)3-mediated
membrane recruitment of Bam32 is required for the inhib-
itory effect.
Since Bam32 functions downstream of PI3K, and the
role of PI3K in NF-AT activation has not been examined
in B cells, we determined the effect of PI3K inhibitors on
BCR-induced activation of NF-AT in BJAB cells (Fig. 8
D). Both wortmannin and Ly294002 inhibited BCR-
induced NF-AT activation in a dose-dependent manner
(Fig. 8 D), and this inhibition was not due to nonspecific
toxicity of the inhibitors, since PdBu plus ionomycin–
induced NF-AT activation was not significantly affected (data
not shown). This result indicates that BCR-induced NF-AT
activation requires effectors downstream of PI3K, as was
previously found for TCR-induced activation of NF-AT
(43).
Discussion
Studies of genetically deficient animals or humans have
implicated adaptor proteins as critical regulators and inte-
grators of signaling pathways in lymphocytes (44, 45). The
Bam32 molecule described in this report represents a new
and unique addition to the growing family of hematopoi-
etic cell–restricted signaling adaptor proteins that regulate
lymphocyte signal transduction (46, 47). Compared with
the known group of hematopoietic cell–restricted adaptor
proteins, Bam32 is distinguished by its small size and its
simple two-domain structure. Perhaps due to this compact
structure, the Bam32 amino acid sequence is highly con-
served between different species, with mouse Bam32
showing  .90% identity to human (Fig. 1) and chicken
Bam32 showing .80% identity to human (Maeda, A., H.
Niiro, A.J. Marshall, E.A. Clark, and T. Kurosaki, unpub-
lished data).
Expression and Chromosomal Location of Bam32. Bam32
is clearly expressed in B, but not T lymphocytes; however,
the present data do not rule out expression in myeloid or
other hematopoietic lineages. Indeed, Bam32 is expressed
at high levels in the trachea, which contains few lympho-
cytes but significant numbers of dendritic cells (48). Our
preliminary results suggest that Bam32 is expressed in
monocyte-derived dendritic cells (Marshall, A.J., D. Ma-
galetti, and E.A. Clark, unpublished data), which could po-
tentially account for Bam32 expression in the trachea. In
the B lineage, Bam32 is expressed as early as the pre-B cell
stage (Marshall, A.J., and E.A. Clark, unpublished data).
Figure 8. Bam32 inhibits BCR-induced NF-AT activa-
tion in a dose-dependent and PH domain–dependent man-
ner. pcDNA3 expression vectors containing wild-type or
mutant Bam32 were cotransfected into BJAB cells with an
NF-AT-luciferase reporter construct. After 18 h, cells were
harvested and incubated for 6 h with media alone, anti-IgM
F(ab9)2 fragments, or PdBu and ionomycin. The cells were
then lysed and luciferase activity was assayed. The luciferase
activity data are expressed as a percentage of activity ob-
served in the PdBu and ionomycin stimulation and repre-
sent the mean and standard error of triplicate cultures. (A)
Dose-dependent inhibition of NF-AT activation. NF-AT
activity was assayed after stimulation and the level of
Bam32 expression before stimulation was determined by
Western blot analysis. The amounts of expression vector
used in the experiment shown were as follows (from left to
right): 20 mg (empty vector), 1.25, 2.5, 5, 10, or 20 mg
(Bam32 vector). (B) Inhibition of BCR-induced NF-AT
activation requires an intact PH domain. Constructs encod-
ing wild-type, PH domain–deleted (D143–280), or SH2
domain point mutant (R61K) Bam32 were cotransfected
with the NF-AT reporter construct, and assayed as above.
Amounts of plasmids used were 10 mg (empty vector) and 5
or 10 mg (Bam32 vectors). Data are representative of three
experiments. (C) Expression of Bam32 with mutations in
the putative PI(3,4,5)P3-binding motif leads to a modest
augmentation of BCR-induced NF-AT activation. Vector
amounts used were 20 mg (empty vector) and 5 or 10 mg
(Bam32 vectors). Mutant Bam32 proteins are expressed at
similar levels to the wild-type (data not shown). Data are
representative of three experiments. (D) BCR-induced NF-AT activation in BJAB cells requires PI3K activity. BJAB cells were transfected with the NF-
AT luciferase reporter, preincubated with wortmannin (0.32, 1.6, 8, or 40 nM) or Ly294002 (0.4, 2, 10, or 50 mM), and then stimulated and assayed for
NF-AT activity as above in the continuous presence of the inhibitors. Results are representative of two experiments.1327 Marshall et al.
Expression in mature B cells is modulated during activation
and subsequent differentiation, with a marked increase in
expression during the naive to GC B cell transition, and a
dramatic decrease in memory B cells (Fig. 3). Among hu-
man B cell lines, we observe the highest levels of Bam32
protein in the typical Burkitt’s lymphoma lines Ramos and
Daudi (data not shown), which share many features with
GC B cells (49). Finally, we find that cross-linking CD40
on naive B cells, which can turn on some phenotypic char-
acteristics of GC B cells (50), leads to a rapid increase in
Bam32 expression (Fig. 3 B). Interestingly, BCR ligation
alone does not significantly affect Bam32 expression, and
does not affect upregulation when used in combination
with CD40 ligation, suggesting that transcription of Bam32
is specifically CD40 responsive. Together, these data
strongly suggest that Bam32 expression is increased during
T cell–dependent B cell activation and the subsequent GC
response. It is tempting to speculate that Bam32 upregula-
tion may be an important factor in the cross-talk between
CD40 and BCR signaling pathways and/or in tuning B cell
responses to antigen during affinity maturation in GCs.
The human Bam32 gene is located on chromosome 4
q25–q27, an interval containing several other immunologi-
cally relevant genes such as IL-2, epidermal growth factor,
fibroblast growth factor 2, caspase 6, I factor (complement),
and lymphoid enhancer-binding factor 1. Consistent with
the chromosomal assignment, the Bam32 cDNA sequence
matches a sequence-tagged site (STS) on chromosome 4
(data not shown). Interestingly, loss of this region of chro-
mosome 4 is observed in many Hodgkin’s lymphomas (51),
which are thought to originate from GC B cells (52).
Given that Bam32 may negatively regulate NF-AT activa-
tion in B cells, it will be important to determine whether
defects in Bam32 expression could contribute to increased
B cell proliferation and potentially malignant transforma-
tion in Hodgkin’s lymphoma.
Tyrosine Phosphorylation of Bam32. Bam32 is tyrosine
phosphorylated after BCR ligation, indicating that it is a
target of a kinase activated downstream of the BCR. While
Bam32 contains 10 tyrosine residues, only 1 (Y139)
matches the general consensus motif for a tyrosine phos-
phorylation site in which a basic followed by an acidic
amino acid are present 4–6 residues NH2-terminal to the
tyrosine. This tyrosine lies in an SIYESV motif, which fits
the preferred target sequence for src family kinases (I/L-Y-
D/E), but not for syk kinase (D-Y-E) (53). When phos-
phorylated, this site could form a target for binding of some
SH2 domain–containing proteins (54). The phosphoryla-
tion of Bam32 correlates with a bandshift of 2–3 kD on our
SDS-PAGE gels, suggesting that either (a) phosphorylation
at tyrosine 139 leads a stable conformational change that re-
tards the migration of Bam32, (b) phosphorylation at ty-
rosine 139 is upstream of multiple phosphorylations by
serine/threonine kinases, or (c) Bam32 is phosphorylated
on multiple tyrosines not conforming to the consensus ty-
rosine-phosphorylation site. We have found that phosphor-
ylated Bam32 is poorly recognized by our mAb, consistent
with a stable conformational change. Interestingly, prelimi-
nary evidence indicates that Bam32 phosphorylation is in-
hibited by wortmannin pretreatment (Niiro, H., A.J.
Marshall, and E.A. Clark, unpublished), suggesting that
membrane recruitment of Bam32 is required for its phos-
phorylation and/or that activation of the kinase responsible
is dependent on PI3K activity.
Structure and Function of the Bam32 SH2 Domain.
BLAST sequence similarity searching (available at http://
www.ncbi.nlm.nih.gov/BLAST) indicated that the Bam32
SH2 domain is most highly related (30–37% identity) to
those of the adaptor protein Nck, PLCg1, PI3K p85 sub-
unit, and the protein tyrosine phosphatases SHP-1 and
SHP-2. The Bam32 SH2 domain shows the greatest overall
similarity with the Nck SH2 domain (37% identity, 62%
similarity), including identical residues at the bD3 and bD5
positions, which are thought to be critical in determining
specificity of binding to phosphotyrosine motifs (55). De-
spite the similarity with the Nck SH2 domain, we have
been unable to detect association of Bam32 with proteins
known to associate with Nck in activated lymphocytes
such as BLNK, p62 DOK, and p120 Ras-GAP (Niiro, H.,
A.J. Marshall, and E.A. Clark, unpublished data). How-
ever, we can clearly detect association of Bam32 with
PLCg2 in vivo. Our results indicate that the Bam32 SH2
domain can directly bind phosphorylated PLCg2 in vitro;
however, we cannot exclude the possibility that the in vivo
interaction is mediated by another protein. The finding
that PLCg2 but not PLCg1 can be detected in Bam32 im-
munoprecipitates is intriguing, and could be due to differ-
ences in the tyrosine-phosphorylation motifs present in
these two isoforms (56). However, we did detect some
binding of the Bam32 SH2 domain to tyrosine-phosphory-
lated PLCg1 in vitro, so we cannot completely exclude the
possibility of a low stoichiometry association between
Bam32 and PLCg1 in vivo.
Structure and Function of the Bam32 PH Domain. The
PH domain of Bam32 appears to be both necessary and suf-
ficient for membrane association of Bam32 (Fig. 6 A). We
have observed no significant differences in the behavior of
the full-length Bam32 fusion protein and the PH domain
fusion protein in terms of the level of basal or induced
membrane association or the sensitivity of membrane asso-
ciation to PI3K inhibitors; however, the present experi-
ments do not rule out a contribution of the SH2 domain in
regulating Bam32 localization. The PH domain of Bam32
is related (39% identity) to those of Grp1, cytohesin-1, and
ADP ribosylation factor nucleotide binding site opener
(ARNO), which bind to 3-phosphoinositides generated by
PI3K (57–60). Bam32, like Grp1, Akt, and Btk also con-
tains a series of conserved residues in the b1 and b2 strands
of the PH domain that correlate with the ability to bind
3-phosphoinositides (32). Thus, the structure of the Bam32
PH domain is consistent with the hypothesis that it func-
tions as a mediator of PI3K-dependent membrane associa-
tion through binding of 3-phosphoinositides. Indeed, we
find that association of Bam32 with the plasma membrane
is strictly dependent on PI3K activity and an intact
PI(3,4,5)P3-binding motif in the PH domain. During prep-1328 Bam32: A Novel Adaptor Protein Regulating B Cell Activation
aration of this manuscript, a molecule identical to Bam32
was described under the name DAPP1, for dual adaptor for
phosphotyrosine and 3-phosphoinositides (61). In that re-
port, the PH domain of DAPP1 was found to bind in vitro
to the PI3K products PI(3,4,5)P3 and PI(3,4)P2, consistent
with our in vivo findings of PI3K-dependent membrane
recruitment.
Btk is another example of a B cell–specific protein that is
recruited to the plasma membrane through its PH domain
in a PI3K-dependent manner, through direct binding to
PI(3,4,5)P3 (14, 33, 62). PH domain–dependent membrane
recruitment of Btk is functionally relevant because point
mutations that prevent membrane recruitment block Btk
activation, leading to defective B cell development in
X-linked agammaglobulinemia (14, 34), and point mutations
that cause constitutive membrane association lead to consti-
tutively active Btk (14, 38). Interestingly, direct compari-
son of the membrane recruitment of the Bam32 versus Btk
PH domains indicated that the Bam32 PH domain associ-
ates with the plasma membrane of activated B cells with
higher stoichiometry than the Btk PH domain (Fig. 6 B).
Since our analysis considers the ratio of localization to the
membrane versus the cytoplasm, this difference could be
accounted for by a difference in their relative affinity for
phosphoinositide ligands in the membrane or differences in
affinity for potential protein ligands in the membrane or
cytoplasm. The Bam32/DAPP1 PH domain was estimated
to bind PI(3,4,5)P3 with an affinity of 3 nM, compared
with 60 nM for 3-phosphoinositide–dependent kinase 1
(PDK1), which was used as an internal control in that study
(61). In contrast, the Btk PH domain was estimated to bind
PI(3,4,5)P3 with an affinity of 800 nM (62). Thus, the
Bam32 PH domain appears to bind PI(3,4,5)P3 with an un-
usually high affinity.
Role of Bam32 in B Cell Activation. The restricted ex-
pression pattern of Bam32, together with its upregulation
during B cell activation, strongly suggests that Bam32 func-
tions as a specific regulator of B cell signaling pathways.
Regulation of Bam32 levels during B cell differentiation
(Fig. 3) could potentially modulate the stoichiometry and/
or kinetics of membrane-associated signaling complexes
formed downstream of PI3K activation, thus altering the
downstream consequences of activation signals. Given the
apparent hierarchy of affinities present in PI(3,4,5)P3-bind-
ing proteins (Bam32®PDK1®Btk/Akt), it seems likely
that Bam32 is one of the first proteins recruited during acti-
vation of PI3K and/or that Bam32 can be recruited by
lower levels of PI3K activation than these other proteins.
Consistent with this idea, our data indicate that basal levels
of PI(3,4,5)P3 may be sufficient for some Bam32 to associ-
ate with the plasma membrane so that Bam32 is at the
membrane before BCR activation. Our present hypothesis,
which we are currently testing, is that Bam32 regulates the
activity of protein kinases that are recruited later in the
PI3K-dependent cascade, such as Btk or Akt.
Our results indicate that one downstream effect of in-
creasing Bam32 levels is an inhibition of BCR-induced ac-
tivation of NF-AT. Although it is difficult to conclude
simply from overexpression studies what precise role
Bam32 plays in BCR signaling, it is clear that Bam32 can
regulate the BCR signal transduction upstream of NF-AT.
Activation of NF-AT transcriptional activity in B cells, as
in T cells, requires both Ca21 mobilization and PKC acti-
vation (17, 18). We find that treatment of BJAB B cells
with PI3K inhibitors leads to inhibition of BCR-induced
NF-AT activation (Fig. 8 D), indicating that the PI3K
pathway recruits essential effectors upstream of NF-AT ac-
tivation in B cells. The requirement for PI3K in NF-AT
activation may reflect, at least in part, the role of PI3K in
activation of PLCg and subsequently Ca21 mobilization
(63). Recent work has implicated Btk as a PI3K-dependent
effector which is required for full activation of PLCg lead-
ing to influx of Ca21 across the plasma membrane (64).
Since Bam32 binds the same phospholipid as Btk and asso-
ciates with PLCg2, it is tempting to speculate that Bam32
could regulate the activation of PLCg2 by Btk. Overex-
pression of Bam32 in BJAB cells to levels that inhibit NF-
AT activation by .50% does not lead to detectable
changes in BCR-induced Ca21 flux (data not shown);
however, it remains possible that Bam32 regulates the sus-
tained phase of the Ca21 response, which is Btk dependent
(63, 64) and critical for full activation of NF-AT–depen-
dent transcription (65, 66). Another possibility is that
Bam32 could modulate NF-AT activation by regulating
Ca21-independent signaling events downstream of PI3K,
such as Akt activation (11). Akt could regulate NF-AT ac-
tivation through phosphorylation and inhibition of glyco-
gen synthase kinase 3 (67), whose activity opposes cal-
cineurin-dependent translocation of NF-AT to the nucleus
(68). Expression of constitutively active Akt enhances
TCR-induced NF-AT activation (43), consistent with a
role for Akt in NF-AT activation.
The PI3K pathway has been shown to be essential for B
cell activation and differentiation in studies examining the
effect of PI3K inhibitors on B cell responses in vitro (69–
71) and the effect of PI3K p85a deficiency in mice (72,
73). Furthermore, the PI3K pathway is subject to opposing
regulation by the CD19 coreceptor, which recruits PI3K to
the antigen receptor complex (74), and the inhibitory Fc
receptor FcgRII, which specifically antagonizes the PI3K
pathway by recruiting the inositol phosphatase SHIP (13).
Bam32 is clearly a novel component of this critical PI3K
activation pathway in B lymphocytes, and our results sug-
gest that it may specifically regulate PI3K-dependent effec-
tors involved in activation of NF-AT. Modulation of
BCR-induced NF-AT activation by Bam32 could have
important functional consequences for B cells, since B cells
from NF-ATc–deficient mice have diminished prolifera-
tive responses to a variety of stimuli, including BCR or
CD40 ligation (39, 40). In contrast, B cells from NF-ATp–
deficient mice are hyperproliferative (42) and B cells from
NF-AT4–deficient mice show an activated phenotype in
vivo (41). We speculate that upregulation of Bam32 during
the GC response may lead to qualitative changes in BCR
signaling to the nucleus necessary for the exquisitely sensi-
tive process of selection based on affinity for antigen.1329 Marshall et al.
We thank Dr. Gary Koretzky for providing the NF-AT luciferase
reporter construct, Geraldine Shu for assistance with preparing hu-
man FDCs, Kevin Draves for help in preparing the anti-Bam32
mAb, Sasha Solow and Dario Magaletti for help with preparation
and culture of resting B cells, Cathy Allen for help with flow cy-
tometry, Dave Coder for advice regarding confocal microscopy,
and Drs. Andrew Craxton and Tom Yankee for critical reading of
the manuscript. We are very grateful to all of the members of the
Clark laboratory for advice and helpful discussions.
This work was supported by National Institutes of Health grants
AI44257, GM37905, DE08229, and AI45088 (to E.A. Clark). A.J.
Marshall is supported by a Medical Research Council of Canada
postdoctoral fellowship. H. Niiro is supported by grants from the
Yoshitomi Medical Research Foundation and the Clinical Re-
search Foundation of Japan.
Submitted: 29 November 1999
Revised: 15 February 2000
Accepted: 23 February 2000
References
1. Craxton, A., K.L. Otipoby, A. Jiang, and E.A. Clark. 1999.
Signal transduction pathways which regulate the fate of B
lymphocytes. Adv. Immunol. 73:79–152.
2. Kurosaki, T. 1999. Genetic analysis of B cell antigen receptor
signaling. Annu. Rev. Immunol. 17:555–592.
3. Lam, K.-P., R. Kuhn, and K. Rajewsky. 1997. In vivo abla-
tion of surface immunoglobulin on mature B cells by induc-
ible gene targeting results in rapid cell death. Cell. 90:1073–
1083.
4. Healy, J.I., and C.C. Goodnow. 1998. Positive versus nega-
tive signaling by lymphocyte antigen receptors. Annu. Rev.
Immunol. 16:645–670.
5. Nossal, G.J. 1983. Cellular mechanisms of immunological
tolerance.  Annu. Rev. Immunol. 1:33–62.
6. Healy, J.I., R.E. Dolmetsch, L.A. Timmerman, J.G. Cyster,
M.L. Thomas, G.R. Crabtree, R.S. Lewis, and C.C. Good-
now. 1997. Different nuclear signals are activated by the B
cell receptor during positive versus negative signaling. Immu-
nity. 6:419–428.
7. Coggeshall, K.M. 1998. Inhibitory signaling by B cell Fc
gamma RIIb. Curr. Opin. Immunol. 10:306–312.
8. Fujimoto, M., J.C. Poe, M. Inaoki, and T.F. Tedder. 1998.
CD19 regulates B lymphocyte responses to transmembrane
signals. Semin. Immunol. 10:267–277.
9. Harwood, A.E., and J.C. Cambier. 1993. B cell antigen re-
ceptor cross-linking triggers rapid protein kinase C indepen-
dent activation of p21ras1. J. Immunol. 151:4513–4522.
10. Gold, M., V. Chan, T. CW, and A. DeFranco. 1992. Mem-
brane Ig cross-linking regulates phosphatidylinositol 3-kinase
in B lymphocytes. J. Immunol. 148:2012–2022.
11. Craxton, A., A. Jiang, T. Kurosaki, and E.A. Clark. 1999.
Syk and Bruton’s tyrosine kinase are required for B cell anti-
gen receptor-mediated activation of the kinase Akt. J. Biol.
Chem. 274:30644–30650.
12. Aman, M.J., T.D. Lamkin, H. Okada, T. Kurosaki, and K.S.
Ravichandran. 1998. The inositol phosphatase SHIP inhibits
Akt/PKB activation in B cells. J. Biol. Chem. 273:33922–
33928.
13. Bolland, S., R.N. Pearse, T. Kurosaki, and J.V. Ravetch.
1998. SHIP modulates immune receptor responses by regu-
lating membrane association of Btk. Immunity. 8:509–516.
14. Varnai, P., K.L. Rother, and T. Balla. 1999. Phosphatidyl-
inositol 3-kinase-dependent membrane association of the
Bruton’s tyrosine kinase pleckstrin homology domain visual-
ized in single living cells. J. Biol. Chem. 274:10983–10989.
15. Fu, C., C.W. Turck, T. Kurosaki, and A. Chan. 1998.
BLNK: a central linker protein in B cell activation. Immunity.
9:93–103.
16. Ishiai, M., M. Kurosaki, R. Pappu, K. Okawa, I. Ronko, C.
Fu, M. Shibata, A. Iwamatsu, A.C. Chan, and T. Kurosaki.
1999. BLNK required for coupling Syk to PLC gamma 2
and Rac1-JNK in B cells. Immunity. 10:117–125.
17. Choi, M.S.K., R.D. Brines, M.J. Holman, and G.G.B.
Klaus. 1994. Induction of NF-AT in normal B lymphocytes
by anti-immunoglobulin or CD40 ligand in conjunction
with IL-4. Immunity. 1:179–187.
18. Venkataraman, L., D.A. Francis, Z. Wang, J. Liu, T.L.
Rothstein, and R. Sen. 1994. Cyclosporin-A sensitive in-
duction of NF-AT in murine B cells. Immunity. 1:189–196.
19. Clipstone, N.A., and G.R. Crabtree. 1994. Signal transduc-
tion between the plasma membrane and the nucleus of T
lymphocytes. Annu. Rev. Biochem. 63:1045–1083.
20. Baeuerle, P.A., and T. Henkel. 1994. Function and activa-
tion of NF-kB in the immune system. Annu. Rev. Immunol.
12:141–179.
21. Liu, Y.J., and C. Arpin. 1997. Germinal center development.
Immunol. Rev. 156:111–126.
22. MacLennan, I.C.M. 1994. Germinal centers. Annu. Rev. Im-
munol. 12:117–139.
23. Han, S., B. Zheng, Y. Takahashi, and G. Kelsoe. 1997. Dis-
tinctive characteristics of germinal center B cells. Semin. Im-
munol. 9:255–260.
24. Liu, Y.J., J. Xu, O. de Bouteiller, C. Parham, G. Grouard,
O. Djossou, B. de Saint-Vis, S. Lebecque, J. Banchereau,
and K. Moore. 1997. Follicular dendritic cells specifically ex-
press the long CR2/CD21 isoform. J. Exp. Med. 185:165–
170.
25. Edelhoff, S.E., D.E. Ayer, A.S. Zervos, E. Steingrimsson,
N.A. Jenkins, N.G. Copeland, R.N. Eisenman, R. Brent,
and C.M. Disteche. 1994. Mapping of two genes encoding
members of a distinct subfamily of MAX interacting pro-
teins: MAD to human chromosome 2 and mouse chromo-
some 6, and MXII to human chromosome 10 and mouse
chromosome 19. Oncogene. 9:665–668.
26. Barrett, T.B., G.L. Shu, K.E. Draves, A. Pezzutto, and E.A.
Clark. 1990. Signaling through CD19, Fc receptors or trans-
forming growth factor-beta: each inhibits the activation of
resting human B cells differently. Eur. J. Immunol. 20:1053–
1059.
27. Liu, Y.J., C. Barthelemy, O. de Bouteiller, C. Arpin, I. Du-
rand, and J. Banchereau. 1995. Memory B cells from human
tonsils colonize mucosal epithelium and directly present anti-
gen to T cells by rapid up-regulation of B7-1 and B7-2.
Immunity. 2:239–248.
28. Ho, S.N., H.D. Hunt, R.M. Horton, J.K. Pullen, and L.R.
Pease. 1989. Site-directed mutagenesis by overlap extension
using the polymerase chain reaction. Gene. 77:51–59.
29. Leprince, C., K.E. Draves, J.A. Ledbetter, R.M. Torres, and
E.A. Clark. 1992. Characterization of molecular components
associated with surface immunoglobulin M in human B lym-
phocytes: presence of tyrosine and serine/threonine protein
kinases. Eur. J. Immunol. 22:2093–2099.
30. Law, C.L., K.A. Chandran, S.P. Sidorenko, and E.A. Clark.
1996. Phospholipase c-g1 interacts with conserved phospho-1330 Bam32: A Novel Adaptor Protein Regulating B Cell Activation
tyrosyl residues in the linker region of Syk and is a substrate
for Syk. Mol. Cell. Biol. 16:1305–1315.
31. Law, C.L., M.K. Ewings, P.M. Chaudhary, S.A. Solow, T.J.
Yun, A.J. Marshall, L. Hood, and E.A. Clark. 1999. GrpL, a
Grb2-related adaptor protein, interacts with SLP-76 to regu-
late nuclear factor of activated T cell activation. J. Exp. Med.
189:1243–1253.
32. Isakoff, S.J., T. Cardozo, J. Anreev, Z. Li, K.M. Ferguson,
R. Abagyan, M.A. Lemmon, A. Aronheim, and E.Y.
Skolnik. 1998. Identification and analysis of PH domain-
containing targets of phosphatidylinositol 3-kinase using a
novel in vivo assay in yeast. EMBO (Eur. Mol. Biol. Organ.) J.
17:5374–5387.
33. Salim, K., M.J. Bottomley, E. Querfurth, M.J. Zvelebil, I.
Gout, R. Scaif, R.L. Margolis, R. Gigg, C.I.E. Smith, P.C.
Driscoll, et al. 1996. Distinct specificity in the recognition of
phosphoinositides by the pleckstrin homology domains of
dynamin and the Bruton’s tyrosine kinase. EMBO (Eur. Mol.
Biol. Organ.) J. 15:6241–6250.
34. Conley, M.E., and M.D. Cooper. 1998. Genetic basis of ab-
normal B cell development. J. Exp. Med. 10:399–406.
35. Rawlings, D., D. Saffran, S. Tsukada, D. Largaespada, J.C.
Grimaldi, L. Cohen, R. Mohr, J.F. Bazan, M. Howard, N.
Copeland, et al. 1993. Mutation of unique region of Bru-
ton’s tyrosine kinase in immunodeficient XID mice. Science.
261:358–361.
36. Baraldi, E., K.D. Carugo, M. Hyvonen, P.L. Surdo, A.M.
Riley, B.V. Potter, R. O’Brien, J.E. Ladbury, and M. Sa-
raste. 1999. Structure of the PH domain from Bruton’s ty-
rosine kinase in complex with inositol 1,3,4,5-tetrakisphos-
phate. Structure. 7:449–460.
37. Hyvonen, M., and M. Saraste. 1997. Structure of the PH do-
main and Btk motif from Bruton’s tyrosine kinase: molecular
explanations for X-linked agammaglobulinaemia. EMBO
(Eur. Mol. Biol. Organ.) J. 16:3396–3404.
38. Li, T., S. Tsukuda, A. Satterthwiate, M.H. Havlik, H. Park,
K. Takatsu, and O.N. Witte. 1995. Activation of Bruton’s
tyrosine kinase (BTK) by a point mutation in its pleckstrin
homology (PH) domain. Immunity. 2:451–460.
39. Yoshida, H., H. Nishina, H. Takimoto, L.E. Marengere,
A.C. Wakeham, D. Bouchard, Y.Y. Kong, T. Ohteki, A.
Shahinian, M. Bachmann, et al. 1998. The transcription fac-
tor NF-ATc1 regulates lymphocyte proliferation and Th2
cytokine production. Immunity. 8:115–124.
40. Ranger, A.M., M.R. Hodge, E.M. Gravallese, M. Oukka, L.
Davidson, F.W. Alt, F.C. de la Brousse, T. Hoey, M.
Grusby, and L.H. Glimcher. 1998. Delayed lymphoid repop-
ulation with defects in IL-4-driven responses produced by
inactivation of NF-ATc. Immunity. 8:125–134.
41. Oukka, M., I.C. Ho, F. Charles de la Brousse, T. Hoey, M.J.
Grusby, and L.H. Glimcher. 1998. The transcription factor
NF-AT4 is involved in the generation and survival of T cells.
Immunity. 9:295–304.
42. Hodge, M.R., A.M. Ranger, F.C. de la Brousse, T. Hoey,
M.J. Grusby, and L.H. Glimcher. 1996. Hyperproliferation
and dysregulation of IL-4 expression in NF-ATp-deficient
mice. Immunity. 4:397–405.
43. Eder, A.M., L. Dominguez, T.F. Frannke, and J.D. Ashwell.
1998. Phosphoinositide 3-kinase regulation of T cell recep-
tor-mediated interleukin-2 gene expression in normal T
cells.  J. Biol. Chem. 273:28025–28031.
44. Clements, J.L., B. Yang, S.E. Ross-Barta, S.L. Eliason, R.F.
Hrstka, R.A. Williamson, and G.A. Koretzky. 1998. Re-
quirement for the leukocyte-specific adaptor protein SLP-76
for normal T cell development. Science. 281:416–419.
45. Sayos, J., C. Wu, M. Morra, N. Wang, X. Zhang, D. Allen,
S. van Schaik, L. Notarangelo, R. Geha, M.G. Roncarolo,
et al. 1998. The X-linked lymphoproliferative-disease gene
product SAP regulates signals induced through the co-recep-
tor SLAM. Nature. 395:462–469.
46. Clements, J.L., N.J. Boerth, J.R. Lee, and G.A. Koretzky.
1999. Integration of T cell receptor-dependent signaling
pathways by adaptor proteins. Annu. Rev. Immunol. 17:89–
108.
47. Rudd, C.E. 1999. Adaptors and molecular scaffolds in im-
mune cell signaling. Cell. 96:5–8.
48. McWilliam, A.S., D.J. Nelson, and P.G. Holt. 1995. The bi-
ology of airway dendritic cells. Immunol. Cell Biol. 73:405–
413.
49. Ling, N.R., D. Hardie, J. Lowe, G.D. Johnson, M. Khan,
and I.C. MacLennan. 1989. A phenotypic study of cells from
Burkitt lymphoma and EBV-B-lymphoblastoid lines and
their relationship to cells in normal lymphoid tissues. Int. J.
Cancer. 15:112–118.
50. Galibert, L., N. Burdin, B. de Saint-Vis, P. Garrone, C. Van
Kooten, J. Banchereau, and F. Rousset. 1996. CD40 and B
cell antigen receptor dual triggering of resting B lymphocytes
turns on a partial germinal center phenotype. J. Exp. Med.
183:77–85.
51. Atkin, N.B. 1998. Cytogenetics of Hodgkin’s disease. Cyto-
genet. Cell. Genet. 80:23–27.
52. Kuppers, R., and K. Rajewsky. 1998. The origin of
Hodgkin and Reed/Sternberg cells in Hodgkin’s disease.
Annu. Rev. Immunol. 16:471–493.
53. Schmitz, R., G. Baumann, and H. Gram. 1996. Catalytic
specificity of phosphotyrosine kinases Blk, Lyn, c-Src and
Syk as assessed by phage display. J. Mol. Biol. 260:664–677.
54. Songyang, Z., S.E. Shoelson, M. Chaudhuri, G. Gish, T.
Pawson, W.G. Haser, F. King, T. Roberts, S. Ratnofsky,
R.J. Lechleider, et al. 1993. SH2 domains recognize specific
phosphopeptide sequences. Cell. 12:767–778.
55. Songyang, Z., G. Gish, G. Mbamalu, T. Pawson, and L.C.
Cantley. 1995. A single point mutation switches the specific-
ity of group III Src homology (SH) 2 domains to that of
group I SH2 domains. J. Biol. Chem. 270:26029–26032.
56. Noh, D.Y., S.H. Shin, and S.G. Rhee. 1995. Phosphoinosi-
tide-specific phospholipase C and mitogenic. Biochim. Bio-
phys. Acta. 1242:99–113.
57. Chardin, P., S. Paris, B. Antonny, S. Robineau, S. Beraud-
Dufour, C.L. Jackson, and M. Chabre. 1996. A human ex-
change factor for ARF contains Sec7- and pleckstrin-homol-
ogy domains. Nature. 384:481–484.
58. Karlund, J.K., A. Guilherme, J.J. Holik, A. Virbasius, and
M.P. Czech. 1997. Signaling by 3,4,5-phosphoinositide
through proteins containing pleckstrin and Sec7 homology
domains. Science. 275:1927–1930.
59. Kolanus, W., W. Nagel, B. Shiller, L. Zeitlmann, S. Godar,
H. Stockinger, and B. Seed. 1996. Alpha L beta 2 integrin/
LFA-1 binding to ICAM-1 induced by cytohesin-1, a cyto-
plasmic regulatory molecule. Cell. 86:233–242.
60. Venkateswarlu, K., F. Gunn-Moore, P.B. Oatey, J.M.
Tavare, and P.J. Cullen. 1998. Nerve growth factor- and
epidermal growth factor-stimulated translocation of the
ADP-ribosylation factor-exchange factor GRP1 to the
plasma membrane of PC12 cells requires activation of phos-
phatidylinositol 3-kinase and the GRP1 pleckstrin homology1331 Marshall et al.
domain. J. Biochem. 335:139–146.
61. Dowler, S., R.A. Currie, C.P. Downs, and D.R. Alessi.
1999. DAPP1: a dual adaptor for phosphotyrosine and
3-phosphoinositides.  Biochem. J. 342:7–12.
62. Rameh, L.E., A.K. Arvidsson, K.L. Carraway III, A.D. Cou-
villon, G. Rathbun, A. Crompton, B. VanRenterghem,
M.P. Czech, K.S. Ravichandran, S.J. Burakoff, et al. 1997.
A comparative analysis of the phosphoinositide binding spec-
ificity of pleckstrin homology domains. J. Biol. Chem. 272:
22059–22066.
63. Scharenberg, A.M., and J.P. Kinet. 1998. PtdIns-3,4,5-P3: a
regulatory nexus between tyrosine kinases and sustained cal-
cium signals. Cell. 94:5–8.
64. Fluckiger, A.C., Z. Li, R.M. Kato, M.I. Wahl, H.D. Ochs,
R. Longnecker, J.P. Kinet, O.N. Witte, A.M. Scharenberg,
and D.J. Rawlings. 1998. Btk/Tec kinases regulate sustained
increases in intracellular Ca21 following B-cell receptor ac-
tivation. EMBO (Eur. Mol. Biol. Organ.) J. 17:1973–1985.
65. Timmerman, L.A., N.A. Clipstone, S.N. Ho, J.P. Northrop,
and G.R. Crabtree. 1996. Rapid shuttling of NF-AT in dis-
crimination of Ca21 signals and immunosuppression. Na-
ture. 383:837–840.
66. Dolmetsch, R., R. Lewis, C.C. Goodnow, and J.I. Healy.
1997. Differential activation of transcription factors induced
by Ca21 response, amplitude and duration. Nature. 386:
855–858.
67. Cross, D.A., D.R. Alessi, P. Cohen, M. Andjelkovich, and
B.A. Hemmings. 1995. Inhibition of glycogen synthase ki-
nase-3 by insulin mediated by protein kinase B. Nature. 378:
785–789.
68. Beals, C.R., C.M. Sheridan, C.W. Turck, P. Gardner, and
G.R. Crabtree. 1997. Nuclear export of NF-ATc enhanced
by glycogen synthase kinase-3. Science. 275:1930–1934.
69. Aagaard-Tillery, K.M., and D.F. Jelinek. 1996. Phosphati-
dylinositol 3-kinase activation in normal human B lympho-
cytes. Differential sensitivity of growth and differentiation to
wortmannin. J. Immunol. 156:4543–4554.
70. Beckwith, M., R.G. Fenton, I.M. Katona, and D.L. Longo.
1996. Phosphatidylinositol-3-kinase activity is required for
the anti-Ig-mediated growth inhibition of a human B-lym-
phoma cell line. Blood. 87:202–210.
71. Venkataraman, C., G. Shankar, G. Sen, and S. Bondada.
1999. Bacterial lipopolysaccharide induced B cell activation
is mediated via a phosphatidylinositol 3-kinase dependent
signaling pathway. Immunol. Lett. 69:233–238.
72. Suzuki, H., Y. Terauchi, M. Fujiwara, S. Aizawa, Y. Yazaki,
T. Kadowaki, and S. Koyasu. 1999. Xid-like immunodefi-
ciency in mice with disruption of the p85alpha subunit of
phosphoinositide 3-kinase. Science. 283:390–392.
73. Fruman, D.A., S.B. Snapper, C.M. Yballe, L. Davidson, J.Y.
Yu, F.W. Alt, and L.C. Cantley. 1999. Impaired B cell de-
velopment and proliferation in absence of phosphoinositide
3-kinase p85alpha. Science. 283:393–397.
74. Buhl, A.M., C.M. Pleiman, R.C. Rickert, and J.C. Cam-
bier. 1997. Qualitative regulation of B cell antigen receptor
signaling by CD19: selective requirement for PI3-kinase ac-
tivation, inositol-1,4,5-trisphosphate production, and Ca21
mobilization. J. Exp. Med. 186:1897–1910.